Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

William Smits

Allergy & Immunology Fort Wayne, IN Medical Doctor

NPI 1811950462 CMS profile 263967

7222 Engle Road, Fort Wayne, IN 46804

Open in the dashboard

General payments

$203,026

1,338 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, William Smits of Fort Wayne, IN is reported in the CMS Open Payments database as having received $203,026 across 1,338 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $22,588 199
2024 General $28,187 184
2023 General $9,154 179
2022 General $15,718 173
2021 General $49,965 216
2020 General $34,785 188
2019 General $42,628 199

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Smits
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to William Smits were reported at $22,588. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year William Smits Allergy & Immunology median Middle half National median
2019 $42,628 $594 $163–$1,512 $163
2020 $34,785 $426 $106–$1,233 $114
2021 $49,965 $638 $157–$1,708 $132
2022 $15,718 $790 $205–$1,961 $149
2023 $9,154 $852 $220–$2,147 $160
2024 $28,187 $865 $203–$2,267 $164
2025 $22,588 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $91,282 215 payments
  2. Regeneron Healthcare Solutions, Inc. $23,871 76 payments
  3. AbbVie, Inc. $22,096 150 payments
  4. Allergan Inc. $15,189 29 payments
  5. OptiNose US, Inc. $11,946 70 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $10,685 31 payments
  7. GlaxoSmithKline, LLC. $10,032 176 payments
  8. Novartis Pharmaceuticals Corporation $8,051 44 payments
  9. Genzyme Corporation $1,582 58 payments
  10. Pfizer Inc. $1,080 97 payments
  11. Other $7,211 392 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $159,091 88 payments
  2. Food and Beverage $23,857 1,184 payments
  3. Consulting Fee $13,966 8 payments
  4. Travel and Lodging $5,952 51 payments
  5. Education $159 7 payments
Products named General payments · program years 2019–2025
  1. FASENRA Respiratory $39,125 73 payments
  2. AIRSUPRA $38,087 48 payments
  3. DUPIXENT Inflammation And Immunology $23,722 68 payments
  4. UBRELVY Neuroscience $23,272 127 payments
  5. UBRELVY Neuroscience $13,439 28 payments
  6. FASENRA Respiratory $13,088 38 payments
  7. Xhance $11,946 70 payments
  8. TRELEGY ELLIPTA $7,110 89 payments
  9. DUPIXENT Immunology $1,737 72 payments
  10. NUCALA $1,206 52 payments
  11. Other $14,395 841 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 111 drugs

Part D claims

10,139

Median for Allergy/ Immunology: 449

Drug cost

$3,013,651

Median for Allergy/ Immunology: $169,700

Branded share of claims

37.2%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 387 $339,551
Fasenra Pen Benralizumab Brand 49 $293,444
Dupixent Syringe Dupilumab Brand 52 $191,435
Cuvitru Immun Glob G(Igg)/Gly/Iga Ov50 Brand 24 $190,887
Xolair Omalizumab Brand 42 $180,809
Dupixent Pen Dupilumab Brand 46 $177,821
Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 Brand 33 $170,941
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 159 $130,408
Nucala Mepolizumab Brand 27 $128,710
Hizentra Immun Glob G(Igg)/Pro/Iga 0-50 Brand 31 $125,740

The 10 drugs with the highest cost, of 111 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 75 billing codes

Paid by Medicare

$443,822

Of which drugs: $167,109

Medicare patients

662

Average age 72

Services billed

25,776

458 women, 204 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 50%
COPD 34%
Diabetes 26%
Ischemic heart disease 24%
Depression 24%
Chronic kidney disease 19%
Osteoporosis 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 82 82 $6,709
Vaccine for pneumococcal polysaccharide for injection beneath the skin or into muscle, patient 2 years or older 90732 Office 19 19 $2,485
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 226 1,093 $824
Influenza vaccine, trivalent derived from cell cultures 90661 Office 11 11 $397
Injection, methylprednisolone sodium succinate, up to 40 mg J2920 Office 67 77 $207
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 304 1,821 $156
Injection, magnesium sulfate, per 500 mg J3475 Office 109 295 $125
Injection, methylprednisolone sodium succinate, 5 mg J2919 Office 133 534 $121
Injection, ketorolac tromethamine, per 15 mg J1885 Office 31 224 $117
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 15 54 $47

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
$24,840 — —
FASENRA
$705 49 —
DUPIXENT
$513 98 —
TRELEGY ELLIPTA
$234 387 —
TEZSPIRE
$226 14 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

1,338 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record